Avidity Biosciences (RNA) Competitors $48.55 +1.69 (+3.61%) Closing price 04:00 PM EasternExtended Trading$48.54 0.00 (-0.01%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA vs. BNTX, TEVA, GMAB, SMMT, ASND, RDY, VTRS, ROIV, BBIO, and MRNAShould you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Avidity Biosciences vs. Its Competitors BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Dr. Reddy's Laboratories Viatris Roivant Sciences BridgeBio Pharma Moderna BioNTech (NASDAQ:BNTX) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Do analysts prefer BNTX or RNA? BioNTech currently has a consensus price target of $133.96, suggesting a potential upside of 27.89%. Avidity Biosciences has a consensus price target of $67.78, suggesting a potential upside of 39.60%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than BioNTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.64Avidity Biosciences 1 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.95 Is BNTX or RNA more profitable? BioNTech has a net margin of -12.20% compared to Avidity Biosciences' net margin of -4,247.77%. BioNTech's return on equity of -1.84% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets BioNTech-12.20% -1.84% -1.59% Avidity Biosciences -4,247.77%-33.45%-30.22% Does the media favor BNTX or RNA? In the previous week, BioNTech had 11 more articles in the media than Avidity Biosciences. MarketBeat recorded 17 mentions for BioNTech and 6 mentions for Avidity Biosciences. BioNTech's average media sentiment score of 0.61 beat Avidity Biosciences' score of 0.52 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Avidity Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in BNTX or RNA? 15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has better earnings & valuation, BNTX or RNA? Avidity Biosciences has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNTech$2.98B8.46-$719.92M-$1.60-65.47Avidity Biosciences$10.90M649.86-$322.30M-$3.56-13.64 Which has more volatility and risk, BNTX or RNA? BioNTech has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. SummaryBioNTech beats Avidity Biosciences on 10 of the 17 factors compared between the two stocks. Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition Export to ExcelMetricAvidity BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.08B$3.42B$6.17B$10.67BDividend YieldN/A2.24%5.72%4.86%P/E Ratio-13.6423.2129.5928.52Price / Sales649.86477.49578.90129.07Price / CashN/A45.5937.1261.42Price / Book4.0710.3412.046.52Net Income-$322.30M-$52.53M$3.32B$276.75M7 Day Performance-0.47%-0.29%-0.17%0.21%1 Month Performance14.78%10.83%5.75%1.68%1 Year Performance6.94%14.10%65.69%32.79% Avidity Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences2.6268 of 5 stars$48.55+3.6%$67.78+39.6%-1.1%$7.08B$10.90M-13.64190BNTXBioNTech2.6545 of 5 stars$102.30+0.2%$134.32+31.3%-4.2%$24.54B$2.98B-63.946,772News CoverageAnalyst ForecastTEVATeva Pharmaceutical Industries3.7017 of 5 stars$20.02-0.1%$25.57+27.8%+3.0%$22.97B$16.54B-125.0936,830GMABGenmab A/S3.8951 of 5 stars$32.68+2.7%$40.80+24.8%+31.4%$20.42B$3.12B16.422,682Positive NewsShort Interest ↑Analyst RevisionSMMTSummit Therapeutics2.8238 of 5 stars$22.93+7.4%$31.29+36.4%-6.9%$15.86B$700K-22.70110Trending NewsEarnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionASNDAscendis Pharma A/S3.0076 of 5 stars$208.43-0.5%$248.29+19.1%+57.0%$12.93B$393.54M-40.391,017RDYDr. Reddy's Laboratories2.9464 of 5 stars$14.36+0.1%$16.95+18.1%-6.7%$11.97B$3.81B21.7527,811Positive NewsVTRSViatris3.1288 of 5 stars$9.86+1.2%$10.40+5.5%-10.8%$11.36B$14.74B-3.4032,000Analyst ForecastROIVRoivant Sciences2.8749 of 5 stars$16.21+1.1%$19.94+23.0%+53.1%$10.95B$29.05M-23.16860BBIOBridgeBio Pharma4.5561 of 5 stars$55.96+0.8%$63.94+14.3%+113.5%$10.61B$221.90M-13.68400Analyst ForecastMRNAModerna4.2628 of 5 stars$26.74-0.3%$41.81+56.4%-49.7%$10.48B$3.24B-3.555,800Trending NewsAnalyst ForecastGap Down Related Companies and Tools Related Companies BioNTech Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Summit Therapeutics Competitors Ascendis Pharma A/S Competitors Dr. Reddy's Laboratories Competitors Viatris Competitors Roivant Sciences Competitors BridgeBio Pharma Competitors Moderna Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNA) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
